We are continuing our momentum with disciplined execution of our strategic growth plans and productivity improvements – one day at a time – across our company.And the results are flowing to the bottom line,” Ellen said.
Ellen pointed out that DuPont has delivered solid results with year-over-year improvements in pricing, fixed cost productivity, operating margins and return on invested capital. She said the company is aggressively growing in emerging markets, continuing to expand the definition of its addressable markets and is advancing its rich new product pipeline.
“Our R&D is focused on what customers want,” Ellen said. “The unique attributes of our products and services are valued by our customers around the world. In addition, we are leveraging our strong R&D capability across several competencies and advancing our exciting new biomaterials and biofuels products and technologies.
“For 2007, we will remain disciplined and focused on the same priorities that delivered our gains last year,” she said. “We expect our earnings growth to continue, consistent with our outlook for about USD 3.15 per share in 2007.”